课题基金 / 基金详情

Development/production of universal influenza vaccines

Development/production of universal influenza vaccines
通用流感疫苗的开发/生产
批准号：
8556153
负责人：
Richard Schwartz
金额：
$1345.38万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8556153
关键词：
ClinicClinical TrialsContractsDNA VaccinesDevelopmentEvaluationHumanHuman VolunteersImmunityInfluenzaLaboratoriesNational Institute of Allergy and Infectious DiseasePhasePhase II Clinical TrialsPlacebosPlantsProductionSafetySeasonsTechniquesTestingVaccine ProductionVaccinesVirusclinical materialimmunogenicityinfluenza virus vaccinemanufacturing processpreclinical safetyprogramssafety study

项目摘要

项目成果

Richard Schwartz的其他基金

相似基金

相关文献

中文摘要
翻译
将按照现行的良好生产规范（cGMP）生产对多种病毒株具有免疫力的流感疫苗，用于人体临床试验，并发布用于健康人类志愿者的人体临床试验。人们希望这些疫苗能够提供广泛的免疫力，即一种“通用流感疫苗”，在若干年期间对多种毒株具有免疫力，而季节性产品仅对单一季节有用。如果这些试验在人体试验中证明了该疫苗的安全性和免疫原性，则可能会在更大规模的（2期）试验中进行进一步评估，这将需要大规模生产临床试验材料（CTM）。
英文摘要
Influenza vaccines conferring immunity against multiple strains of virus will be manufactured for human clinical trials in compliance with current Good Manufacturing Practices (cGMP) and released for use in human clinical trials in healthy human volunteers. It is hoped that these vaccines will confer broad immunity a "universal influenza vaccine" over a period of several years against multiple strains in contrast to seasonal products that are only useful for a single season. If these trials demonstrate safety and immunogenicity of this vaccine in human trials, further evaluation may take place in larger (Phase 2) trials which will necessitate production of the clinical trial materials (CTM) at large scale.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development And Production Of Filovirus DNA Plasmid Vaccines
Production of a Broadly Neutralizing HIV Antibody (VRC01)
HIV LCMV vaccines
Development/production of universal influenza vaccines
海外基金